Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasms

Qi Zhang; Qi Han; Jie Zi; Jinlong Ma; Huihui Song; Yulu Tian; Mary McGrath; Chunhua Song; Zheng Ge

doi:10.1016/j.gendis.2019.05.001

Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasms

Genes Dis. 2019 May 16;6(3):276-281. doi: 10.1016/j.gendis.2019.05.001. eCollection 2019 Sep.

Authors

Qi Zhang¹, Qi Han¹, Jie Zi¹, Jinlong Ma¹, Huihui Song¹, Yulu Tian¹, Mary McGrath², Chunhua Song², Zheng Ge¹

Affiliations

¹ Department of Hematology, Zhongda Hospital Southeast University, Institute of Hematology Southeast University, Nanjing 210009, China.
² Department of Pediatrics, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.

Abstract

EZH2 is a component of the polycomb repressive complex 2 (PRC2), which is a highly conserved histone methyltransferase that methylates lysine 27 of histone 3. EZH2 mutations are associated with oncogenesis and progression of cancers. However, the relationship between the clinical outcome of patients with myeloid malignancies and EZH2 mutations is controversial. Therefore, we performed a meta-analysis of 8 studies (n = 2243 patients) that evaluates the correlation between EZH2 mutations and overall survival (OS) in patients with myeloid neoplasms. EZH2 mutations were associated with significantly worse OS (hazard ratio [HR] = 2.37, 95% confidential interval (CI), 1.48-3.79). In a word, EZH2 mutations indicate a poor prognosis for patients with myeloid neoplasms.

Keywords: EZH2; Meta-analysis; Mutations; Myeloid neoplasms; Prognostic.